Clinical Trial Update: A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 study evaluating how Radium-223 distributes in the body of men with bone-metastatic castration-resistant prostate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Xofigo (radium-223 dichloride)

Snippet

Sponsor: Bayer | Conditions: Bone Metastatic Castration-resistant Prostate Cancer | Phase 1 | Status: COMPLETED